Current stock page

Stock Analysis

Twist Bioscience Corporation (TWST) Stock Analysis

Twist Bioscience Corporation (TWST) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

TWST Stock Analysis Summary

Twist Bioscience Corporation (TWST) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 84/100. Risk is the weakest current factor at 32/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

TWST at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$111.60
AIQ Score64/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Sell
Market Cap$6.96B
P/E Ratio (TTM)-53.65
Forward P/E—
EPS (Q4 FY2026)-$0.31
Revenue (Q4 FY2026)$126.64M
Dividend Yield (TTM)0.00%
Beta2.9
Volume2.05M
52-week range$23.30-$219.71
RSI 1437.87
50-Day SMA$150.23
200-Day SMA$93.24
Analyst Price Target$167.57
Next EarningsJan 29, 2027
As of Nov 13, 2026 · Market close

TWSTTwist Bioscience Corporation

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 7/10
$111.60−$2.62 (−2.29%)

Latest quote

  • Momentum
    84
  • Value
    58
  • Quality
    59
  • Risk resilience
    32
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

TWST Stock Analysis Summary

Twist Bioscience Corporation (TWST) currently has an AIQ Score of 64/100, indicating a neutral setup. Momentum is the strongest factor at 84/100. Risk resilience is the weakest current factor at 32/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, TWST has AIQ Score of 64/100 with Momentum base of 84/100 and fading Risk resilience at 32/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (84/100) leads while Risk resilience (32/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -2.29% stock move · TWST classified in Biotechnology.

Current Evidence

NeutralTWST is in a neutral AIQ regime; Momentum is the strongest visible factor at 84/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is TWST Bullish or Bearish Right Now?

TWST currently has a neutral overall setup. Momentum is the strongest factor at 84/100, while Risk Resilience is weakest at 32/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Momentum is constructive at 84/100.
  • - Analyst target implies +50.15% upside from the latest quote.
Bear Case
  • - Risk Resilience is weak at 32/100.
  • - Technical consensus has more sell votes than buy votes (35 vs 6).

Current Consensus

TWST's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 5 neutral, and 35 sell votes. TWST's 14-day RSI is 37.87, which places the stock in a weaker momentum range. TWST's beta is 2.9, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in TWST?

The largest recent change in TWST is Momentum moving down by 6.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
-1.0
Momentum
-6.0
Quality
+1.0
Risk
-1.0

What Would Change the TWST Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

TWST Decision Framework

Public evidence layers, setup checks, and risk context for Twist Bioscience Corporation.

Twist Bioscience Corporation (TWST) Stock Analysis

Twist Bioscience Corporation has an AIQ Score of 64/100 in a Neutral regime. Momentum is strongest at 84/100. Beta is 2.9, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextTWST is in a Neutral AIQ regime with score 64/100.
Signal ConflictThe primary conflict is that momentum leads at 84/100 while risk lags at 32/100.
Factor EvidenceMomentum 84/100 · Value 58/100 · Quality 59/100 · Risk 32/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 84/100.

TimingPass

Momentum is 84/100 and RSI (14) is 37.9.

Regime fitWait

TWST is in a Neutral regime at 64/100.

Risk controlFail

Risk factor is 32/100 with beta 2.9 and annual volatility 84.18%.

ConflictWait

Current conflict: momentum leads at 84/100 while risk lags at 32/100.

AIQ Score
64/100
Price
$111.60
Beta
2.9
RSI (14)
37.9

TWST Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

TWST Fundamentals

TWST valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$126.64M
Net income
-$20.62M
Free cash flow
-$8.55M
View full TWST fundamental analysis

TWST Technical Analysis

TWST technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
37.87
Price vs SMA-50
-25.71%
View full TWST technical analysis

TWST Stock Catalysts

Track TWST earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Jan 29, 2027
Analyst target
$167.57
News items
4
View TWST earnings and stock catalysts

TWST Dividend Analysis

TWST dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View TWST dividend history and analysis

TWST Financial Data

TWST revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$126.64M
EPS
-$0.31
Periods
8
View TWST financials

TWST Risk Analysis

TWST volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
2.9
Risk score
32/100
1Y volatility
84.18%
View TWST risk analysis

TWST Stock News

TWST stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read TWST stock news

TWST vs Biotechnology Peers

Current peer cohort: TWST · TYRA · URGN · UTHR · VCEL. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
TWST
Current stock
64/10058/10084/10032/1001.9484.18%Current
TYRA
Tyra Biosciences, Inc.
49/100—27/10045/1000.6567.91%TWST vs TYRA
URGN
UroGen Pharma Ltd.
53/10064/10040/10040/1000.3961.94%TWST vs URGN
UTHR
United Therapeutics Corporation
76/10078/10068/10083/1000.7635.02%TWST vs UTHR
VCEL
Vericel Corporation
77/10065/10090/10064/1000.9345.04%TWST vs VCEL
Pairwise Compare links: TYRA · URGN · UTHR · VCELTWST vs TYRATWST vs URGNTWST vs UTHRTWST vs VCELCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a TWST stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for TWST: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-53.65
As of Nov 13, 2026
Revenue growth
27.91%
Gross margin
52.41%
Current debt / equity
0.11
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$126.64M
Quarter net income
-$20.62M
Quarter free cash flow
-$8.55M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
37.87
MACD
-9.38

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
32/100
Beta
2.9
Annual volatility
84.18%
Max drawdown
-45.56%

TWST Stock FAQ

What is TWST stock price today?

Twist Bioscience Corporation's current stock price is $111.60. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is TWST bullish or bearish right now?

TWST's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is TWST's market cap?

TWST's market cap is $6.96B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is TWST's current P/E ratio?

TWST's current P/E ratio is -53.65 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is TWST's RSI?

TWST's 14-day RSI is 37.87 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is TWST above its 50-day and 200-day moving averages?

TWST is -25.71% from its 50-day SMA and 19.69% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is TWST's next earnings date?

TWST's next earnings date is currently listed as Jan 29, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does TWST pay a dividend?

TWST's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.